Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Launched by MEDICAL UNIVERSITY INNSBRUCK · Jun 3, 2020
Trial Information
Current as of April 28, 2025
Unknown status
Keywords
ClinConnect Summary
COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan, China, and has spread rapidly around the world. Currently, European countries, including Austria, are severely affected. In January 2020, the World Health Organisation declared a "Public Health Event of International Concern" and since 11 March 2020 COVID-19 has been classified as a pandemic. Overall mortality rates vary widely, ranging from 0.5 to 7%. These highly depend on the stringency of ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female and male patients ≥ 18 years.
- • Confirmed infection with SARS-CoV-2 according to the definition of the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection
- • Signed and dated declaration of consent by the patient according to ICH-GCP Guidelines.
- Exclusion Criteria:
- • Female and male patients \< 18 years
- • Pregnancy
- • Dementia
- • Declaration of consent by the patient according to ICH-GCP Guidelines not signed
- • Incapacitated patients
About Medical University Innsbruck
The Medical University of Innsbruck is a leading academic institution dedicated to advancing healthcare through innovative research and clinical excellence. Situated in the heart of the Austrian Alps, it combines a rich tradition of medical education with cutting-edge scientific inquiry. As a prominent sponsor of clinical trials, the university focuses on a broad spectrum of medical fields, emphasizing the translation of research findings into practical applications for patient care. With a commitment to ethical standards and rigorous methodologies, the Medical University of Innsbruck strives to enhance treatment options and improve health outcomes globally through its collaborative efforts in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Innsbruck, Tyrol, Austria
Patients applied
Trial Officials
Ivan Tancevski, Doz. Dr.
Principal Investigator
Medical University Innsbruck, Department Internal Medicine II
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials